Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Orca Bio's Tregzi for graft-versus-host disease prevention in blood cancer patients following Ph3 success
Cell therapy, cancer, regulatory T cells, graft-versus-host disease, allogeneic transplant, blood cancer - Read more

QuantumCell licenses AlzeCure Pharma's Alzheimer's platform ACD856, $12M upfront, $2.2B milestones
Licensing deal, neurological, small molecule, AI/ML, milestone payments, equity investment - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Abivax Ph3 safety data allay cancer concerns for (obefazimod), a miR-124 enhancer for ulcerative colitis
Small molecule, autoimmune, miR-124 enhancer, ulcerative colitis, oral therapy - Read more

Alvotech secures $75M term loan facility, strengthening liquidity for biosimilar pipeline growth
Biosimilars, biologics, CDMO, clinical-stage - Read more

AB Science raises €2.3M ($2.62M) private placement, funding AML and ALS R&D programs
Oncology, small molecule, ALS, rare disease - Read more

Flare Therapeutics raises $85M insider-led Series C, advancing precision transcription factor medicines
Clinical-stage, transcription factors, precision medicine, small molecule - Read more

Telum Therapeutics closes €18M ($20.54M) Series A to advance antimicrobial therapies targeting drug-resistant bacterial pneumonia
Infectious disease, antimicrobial, protein-based therapeutics, AI-driven, platform technology - Read more

Cadrenal Therapeutics plans up to $8.8M private placement for working capital purposes
Biopharmaceutical, autoimmune, thrombotic conditions, clinical-stage - Read more

Likang Life Sciences unveils AI-driven personalized cancer vaccine platform in Beijing, designing treatments within 24 hours
Personalized cancer vaccine, oncology, AI-driven, investment - Read more

AstraZeneca settles Texas Medicaid kickback lawsuit over "free nurses" program for $34M
Pharmaceutical, Medicaid fraud, regulatory, financial - Read more

Plus Therapeutics rebrands as Cerenome, deepening AI strategy for CNS oncology diagnostics and therapeutics
Radiotherapeutic, CNS oncology, strategic, operational - Read more

Ipsen to acquire Memo Therapeutics for up to $796M, targeting rare BK virus kidney transplant complication
Monoclonal antibody, rare disease, major transaction, strategic - Read more

Kimball Electronics acquires European CDMO Helvoet Polymer Technologies for $103M, expanding into Netherlands and India
CDMO, drug delivery, major transaction, strategic - Read more

Anthropic launches Claude Science AI workbench and internal drug discovery program targeting neglected diseases
AI drug discovery platform, rare disease, strategic, competitive - Read more

FDA accepts Sarepta Therapeutics' full approval bid for Amondys 45 (casimersen) and Vyondys 53 (golodirsen) in Duchenne muscular dystrophy despite Ph3 confirmatory trial failure
Antisense oligonucleotide, neurological, exon skipping, Duchenne muscular dystrophy, accelerated approval conversion - Read more

R1 Therapeutics forms scientific advisory board to advance AP306 into global phase 2b trials
Small molecule, renal disease, strategic, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA gene and cell therapy acting director Vijay Kumar steps down amid ongoing leadership turbulence
Gene therapy, rare disease, regulatory, operational - Read more

Angitia Biopharmaceuticals terminates Ph3 trial of (AGA111) BMP-6 candidate for spinal fusion, pivots to earlier-stage assets
Protein therapy, musculoskeletal, antibody, bispecific antibody, osteoporosis, osteogenesis imperfecta - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here